XTL BioPharma released FY2024 Q2 earnings on December 30 (EST), actual revenue USD 0, actual EPS USD -0.5604

Brief Summary

For its second quarter of fiscal year 2024, XTL BioPharma reported zero revenue, an earnings per share (EPS) of -$0.5604, and a net loss of $704,000 .

Impact of The News

Event Analysis: Q2 FY2024 Financial Results